Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

34.52

Mkt cap

Volume

220K

High

35.37

P/E Ratio

16.50

52-wk high

41.61

Low

34.28

Div yield

N/A

52-wk low

22.89

Berenberg analyst Caroline Palomeque has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 9:53 am

Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $54.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:39 pm

The U.S. Patent and Trademark Office has denied a petition for reexamination of a patent covering the active ingredient in Wakix (Pitolisant), a product of Harmony Biosciences. This decision is favorable for Harmony Biosciences.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:06 pm

Harmony Biosciences (NASDAQ:HRMY) has received positive analyst ratings in the last quarter, with 6 bullish and 4 somewhat bullish ratings. The average 12-month price target for the company is $66.3, an increase of 0.96% from the previous average of $65.67.

Portfolio Pulse from Benzinga Insights

August 22, 2023 | 6:00 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:45 pm

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $66.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:07 am

U.S. stocks traded mixed with the Nasdaq Composite gaining around 90 points. Monday.com Ltd reported better-than-expected earnings for its second quarter and raised 2023 revenue guidance. Zynerba Pharmaceuticals shares shot up 280% after Harmony Biosciences announced it will acquire the company for $200 million. Shares of Taysha Gene Therapies and Hanryu Holdings also rose significantly. BioXcel Therapeutics shares dropped 42% after the company reported second-quarter results and announced plans to reduce over 50% of jobs. Shares of Hawaiian Electric Industries were down 38% after Wells Fargo maintained an Underweight rating on the stock and lowered its price target. AMC Entertainment was down, falling 34% after the company received court approval for its revised stock conversion plan.

Portfolio Pulse from Lisa Levin

August 14, 2023 | 6:52 pm

Harmony Biosciences (NASDAQ:HRMY) has announced the acquisition of Zynerba Pharmaceuticals (NASDAQ:ZYNE) for $200 million in cash, expected to be completed in Q4 of 2023. Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing therapies for rare neurological diseases. Zynerba Pharmaceuticals is focused on developing synthetic cannabinoid therapeutics.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 3:10 pm

The article discusses value stocks in the healthcare sector, highlighting five companies: Agile Therapeutics, Helius Medical Tech, Catalyst Biosciences, Harmony Biosciences, and Organon. These companies are considered undervalued based on their low P/E multiples. The article also notes improvements in earnings per share for all five companies and an increase in Organon's dividend yield.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 2:44 pm

Harmony Biosciences (NASDAQ:HRMY) announced it will acquire Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) for $200 million. The purchase price is $1.1059 per share in cash, or $60 million in aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million. Zynerba's shares are up by more than 280% at $1.29.

Portfolio Pulse from Erica Kollmann

August 14, 2023 | 2:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.